Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1860668 | 0.88 | TLR4 (0.58) | TLR4ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL1863220 | 0.86 | TLR4 (0.61) | TLR4ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL1863965 | 0.85 | TLR4 (0.52) | TLR4ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL1861096 | 0.81 | TLR4 (0.55) | TLR4ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL1865305 | 0.80 | TLR4 (0.54) | TLR4ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL1864495 | 0.78 | TLR4 (0.52) | TLR4ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL1870350 | 0.78 | TLR4 (0.57) | TLR4ALDH1A1LMNASMN1; SMN2GAA | |
| SCHEMBL871427 | 0.78 | TLR4 (0.62) | TLR4ALDH1A1SMN1; SMN2GAAHPGD | |
| SCHEMBL16491621 | 0.78 | TLR4 (0.57) | TLR4ALDH1A1LMNASMN1; SMN2HPGD | |
| SCHEMBL10178083 | 0.78 | TLR4 (0.55) | TLR4ALDH1A1LMNASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43858-E1 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-12-11 | — | — | US | disclosed |
| US-7935835-B2 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7935835-B2 | Substituted cycloalkene derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1935879-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
| EP-1935879-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233952-A1 | SUBSTITUTED CYCLOALKENE DERIVATIVE | CD40, LITAF, TNF | TLR4 29/4885ALDH1A1 4252/4885LMNA 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.